Results 61 to 70 of about 21,080,479 (286)

Pneumocystis jirovecii pneumonia after CD4+ T‐cell recovery subsequent to CD19‐targeted chimeric antigen receptor T‐cell therapy: A case report and brief review of literature

Cancer Reports, 2023
Background CD19‐targeted chimeric antigen receptor (CAR)‐T cell therapy involves administration of patient‐derived T cells that target B cells, resulting in B‐cell depletion and aplasia.
Kento Kawata, Haruko Shima, Masayoshi Shinjoh, Fumito Yamazaki, Takumi Kurosawa, Mizuki Yaginuma, Hiroshi Takada, Hiroyuki Shimada   +7 more
doaj   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity

Frontiers in Immunology
Chimeric Antigen Receptor (CAR)-T cell therapy has rapidly emerged as a groundbreaking approach in cancer treatment, particularly for hematologic malignancies. However, the application of CAR-T cell therapy in solid tumors remains challenging.
Yaojie Kong, Jingyao Li, Xueyao Zhao, Yanwei Wu, Liang Chen   +4 more
doaj   +1 more source

CAR-T cell therapy in nephrology

Renal Failure
In recent years, chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising immunotherapeutic strategy beyond oncology, offering new treatment opportunities for immune-mediated kidney diseases. These conditions including systemic lupus erythematosus, ANCA-associated vasculitis, membranous nephropathy, and monoclonal gammopathy-related ...
Tondolo, Francesco, Gessaroli, Elisa, Maritati, Federica, Colombini, Irene, Shkjau, Marinela, La Manna, Gaetano, Comai, Giorgia   +6 more
openaire   +4 more sources

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives [PDF]

Glioblastoma (GBM) is the most common primary malignant brain tumor, with a median overall survival of less than 2 years and a nearly 100% mortality rate under standard therapy that consists of surgery followed by combined radiochemotherapy.
John de Groot, Jeffrey Haegelin, Marco Gallus, Hideho Okada, Haegelin, Jeffrey, Su Phyu, Megan Montoya, Okada, Hideho, Gallus, Marco, Montoya, Megan, de Groot, John, Phyu, Su   +11 more
core   +1 more source

Dynamic fine-tuning of CAR-T cell therapy [PDF]

, 2023
Cancer immunotherapy has transformed cancer treatment, with chimeric antigen receptor (CAR)-T cell therapy being one of the most promising approaches. In the previous issue of Molecular Therapy – Oncolytics, Lainšček et al.1 outline a novel strategy for ...
Geisler Muñoz-Guamuro, Pierre V.M. Trehin, Trehin, Pierre V.M., Munoz-Guamuro, Geisler, Wilfried Weber, Trehin, Pierre V. M., Weber, Wilfried   +6 more
core   +1 more source

Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy

Molecular Oncology, EarlyView.
We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley   +1 more source

CAR T- cell therapy: A promising novel approach for treatment of cancer

Cancer Treatment and Research Communications
Chimeric Antigen Receptor T-cell (CAR-T cell) therapy is a promising cancer treatment that has shown success in treating certain type of cancer. It has demonstrated remarkable efficacy, particularly in hematologic malignancies such as certain types of ...
Mahesh Kumar Posa, Jyoti Singh, Sadia Parveen, Subhranshu Panda   +3 more
doaj   +1 more source

The multifaceted roles of lysosomes in cancer

Molecular Oncology, EarlyView.
Lysosomes support cancer cell adaptation by integrating macromolecule degradation and nutrient recycling with nutrient sensing, inter‐organelle communication and immune regulation. These interconnected functions can promote tumour growth, stress tolerance and therapy resistance, while also creating context‐dependent vulnerabilities that may be ...
Jia Li, Kevin M. Ryan
wiley   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source